Ongoing Assessments & Recent Research.
Easy access to our work
Featured News & Insights.
Learn about our latest work.
Our Origin Story.
ICER President Dr. Steve Pearson explains why he founded an organization to advance the use of evidence to improve health care affordability and access for all patients and their families.
The ICER Impact.
New York Medicaid pursued discounts, many of which were in line with ICER reports, which have saved the state over $500 million
Engaged with over 300 patient groups and patient reps
We recently celebrated our 15th anniversary! Learn more.
We recently published a commentary in Health Affairs about one-time treatments like Zynteglo and Hemgenix. In both of these ICER reports, we analyzed a “shared savings” scenario, which suggests how manufacturers of these one-time therapies, instead of capturing all the avoided downstream medical costs in one giant price tag, could set a lower price and therefore share the innovation windfall with society. Read the full article here.
Easy access to our latest policy papers
Second annual scorecard of barriers to fair access criteria; during ICER’s assessment, five payers revised policies for 11 drugs in ways that bring coverage into concordance with fair access criteria, demonstrating that assessment and greater transparency may lead to positive change
Seven out of 10 high-expenditure drugs had substantial 2021 net price increases that were not supported by new clinical evidence; these increases accounted for $805 million in additional costs over one year.
Additionally, three Medicare Part B drugs with high list price increases in 2020 lacked adequate supporting new evidence, directly raising annual out-of-pocket expenses for Medicare patients by up to $3,200 per year.
ICER received a new grant from The Commonwealth Fund to evaluate procedural and methodological changes that could further support health equity goals in health technology assessment (HTA). The findings from this effort will guide ICER’s update to its value assessment framework and inform the work of other HTA groups worldwide.